This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-25 and is reviewed periodically as new material appears.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Tetrahydrocannabinol (THC) is a cannabinoid found in cannabis. It is the principal psychoactive constituent of Cannabis and one of at least 113 total cannabinoids identified on the plant. Although the chemical formula for THC (C21H30O2) describes multiple isomers, the term THC usually refers to the delta-9-THC isomer with chemical name (−)-trans-Δ9-tetrahydrocannabinol. THC, also known pharmaceutically as dronabinol, is used medically to relieve chemotherapy-induced nausea and HIV/AIDS-related anorexia. Nabiximols, a botanical drug which contains THC, is used medically to treat symptoms of multiple sclerosis, including spasticity and neuropathic pain. THC acts as a partial agonist at CB1 and CB2 cannabinoid receptors. THC can be administered orally, inhaled, or transdermally, with bioavailability and onset varying by route, and is extensively metabolized in the liver to active and inactive metabolites before being excreted in feces and urine. Side effects include red eyes, dry mouth, drowsiness, memory impairment, anxiety, and, with chronic use, cannabinoid hyperemesis syndrome. While human overdose is rare, THC can interact with other drugs and has a complex pharmacokinetic profile.
Liquid Scintillation Counting, University of Wisconsin–Milwaukee Radiation Safety Program Principles and Applications of Liquid Scintillation Counting, National Diagnostics K. Regan, "Cerenkov counting technique for beta particles: advantages and limitations". J. Chem. Educ., August 1983, 60 (8), 682–684. doi:10.1021/ed060p682
International Package operations include delivery to more than 220 countries and territories worldwide, including shipments wholly outside the United States, as well as shipments with either origin or distribution outside the United States. UPS splits its international shipping into a few services:
=== Lithuania === Lithuanian Armed Forces field rations are based on the American MRE. They come in 10 menus packed in a dark green plastic bag, and besides the main meal in a retort pouch they also include two small dark chocolate bars, honey or jam, four hard-tack biscuits, a handful of almonds or hazelnuts, instant drink mix, tea or coffee, sugar, an antiseptic wipe, matches, solid fuel tablets, a flat disposable stove, a flameless heater (similar to the US one) and a cable-tie used to seal waste packaging back into the outer bag after use.
== Structural studies == As of late 2007, 9 structures have been solved for this class of enzymes, with PDB accession codes PDB: 1K4K, PDB: 1K4M, PDB: 1KAM, PDB: 1KAQ, PDB: 1YUL, PDB: 1YUM, PDB: 1YUN, PDB: 2H29, and PDB: 2H2A.
Sources: en.wikipedia.org
=== Tony Day === Tony Day (Stephen Campbell Moore) is Tender’s EMEA CFO, based in Accra and described by Jonah as Whitney’s “lieutenant.” Sweetpea grows suspicious after seeing his name repeatedly in internal emails and learning he was promoted to CFO despite prior career failures, overseeing Tender’s acquisition of an African third-party payment processor. She travels to Accra with Kwabena to investigate. Day is initially evasive but later reveals that recently deceased FinDigest reporter Jim Dycker had discussed potential whistleblowing “pathways” with him. After Sweetpea uncovers evidence that Tender falsified profits in Africa by recycling fake revenue, Day agrees to be interviewed and travels to London to meet her and FinDigest editor Edward Burgess. Whitney intervenes and convinces him to stay loyal, having been warned that the Russian government (for whom Tender is a front) will assassinate Day if he speaks out; Day then appears on a live CNN debate to defend Tender’s African operations, reneging on his agreement with Sweetpea and Burgess. Day is ultimately arrested after Tender's downfall.
== Controversy == The 2014 summary policy statement of the American Academy of Pediatrics (AAP) makes no specific mention of bottle feeding, but makes clear that "[b]reastfeeding and human milk are the normative standards for infant feeding and nutrition", and refers to decisions regarding the supply of infant nutrition as "a public health issue and not only a lifestyle choice… [g]iven the documented short- and long-term medical and neurodevelopmental advantages of breastfeeding". The AAP policy recommends breastfeeding exclusively for six months, continuing it with introduction of complementary foods, with an overall duration of "1 year or longer as mutually desired by mother and infant". The body of the policy statement notes and cites literature indicating that, in addition to the importance of mother's milk, the manner of the food delivery has implications: that "breastfed infants self-regulate intake volume", whereas bottle-fed infants receiving expressed breast milk or formula have "increased bottle emptying, poorer self-regulation, and excessive weight gain in late infancy", and that such early practice of self-regulation correlate with adult patterns of weight gain (ibid.). The AAP policy notes that "[m]edical contraindications to breastfeeding are rare". The transmission of some viral diseases through breastfeeding is reportedly preventable, e.g., by expressing breast milk and subjecting it to Holder pasteurization.
== Prognosis == The prognosis of people with MG is generally good, as is quality of life, when given very good treatment. Monitoring of a person with MG is very important, as at least 20% of people diagnosed with it will experience a myasthenic crisis within two years of their diagnosis, requiring rapid medical intervention. Generally, the most disabling period of MG might be years after the initial diagnosis. Assistive devices may be needed to assist with mobility. In the early 1900s, 70% of detected cases died from lung problems; now, that number is estimated to be around 3–5%, an improvement attributed to increased awareness and medications to manage symptoms.
1993/851) Value Added Tax (General) (Amendment) (No.3) Regulations 1993 (S.I. 1993/856) Social Security (Industrial Injuries and Adjudication) Regulations 1993 (S.I. 1993/861) Social Security (Industrial Injuries) (Prescribed Diseases) Amendment Regulations 1993 (S.I. 1993/862) Official Secrets (Prohibited Places) (Amendment) Order 1993 S.I. 1993/863) Devon and Cornwall Police (Amalgamation) (Amendment) Order 1993 (S.I. 1993/864) West Mercia Police (Amalgamation) (Amendment) Order 1993 (S.I. 1993/865) Sussex Police (Amalgamation) (Amendment) Order 1993 (S.I. 1993/866) Avon and Somerset Police (Amalgamation) (Amendment) Order 1993 (S.I. 1993/867) Thames Valley Police (Amalgamation) (Amendment) Order 1993 (S.I. 1993/868) South Wales Police (Amalgamation) (Amendment) Order 1993 (S.I. 1993/869) Education (Designated Institutions in Further and Higher Education) (Interpretation) (Amendment) Order 1993 (S.I. 1993/870) A13 Trunk Road (Newham, Barking and Dagenham, and Havering) (Speed Limits) Order 1988 (Variation) Order 1993 (S.I. 1993/871) Western Isles Islands Council (Lochmaddy) Water Order 1993 (S.I. 1993/872) Oil Related and Petrochemical Plants (Rateable Values) (Scotland) Order 1993 (S.I. 1993/873) Electricity Generators (Rateable Values) (Scotland) Order 1993 (S.I. 1993/874) Scottish Hydro-Electric plc. (Rateable Values) (Scotland) Order 1993 (S.I. 1993/875) Industrial and Freight Transport (Rateable Values) (Scotland) Order 1993 (S.I. 1993/876) Scottish Nuclear Limited (Rateable Values) (Scotland) Order 1993 (S.I. 1993/877) Scottish Power plc.
Sources: en.wikipedia.org
=== Synthesis === Mescaline was the first ever psychedelic drug synthesized by chemists. Ernst Späth's 1919 total synthesis started from 3,4,5-trimethoxybenzoyl chloride. Several approaches using different starting materials have been developed since, including the following:
In general, cells are cultivated in unlabeled or stable (non-radioactive) isotope labeled media. For example, the medium can contain glucose labeled with six carbon-13 atoms (13C) instead of the normal carbon-12 (12C). Cells growing in this medium, will, depending on model organism, incorporate the heavy glucose into all of their RNA molecules. Thereafter, all nucleotides are 5 Da heavier than their unlabeled isotopologues due to a complete carbon labeling of the ribose. After cultivation and appropriate labeling of the cells, they are generally harvested using phenol/chloroform/guanidinium isothiocyanate. Other extraction methods are possible and sometimes needed (e.g. for yeast). RNA is then isolated by Phenol-Chloroform extraction and iso-Propanol precipitation. Further purification of specific RNA species (e.g. rRNA, tRNA) is usually done by size-exclusion chromatography (SEC) but other approaches are available as well. For most applications the final product needs to be enzymatically digested to nucleosides before analysis by LC-MS. Therefore, digestion enzymes such as benzonase, NP1 and CIP are used. Typically, a triple quadrupole in MRM mode is used for the measurements.
The Lakshman Kadirgamar Institute of International Relations and Strategic Studies is a policy-studies institute that is often referred to as a think tank. LIRNEasia is a think tank working across the Asia-Pacific on regulatory and policy issues. Their main focus is the ICT sector, although they do work in other sectors, such as agriculture and health, which can benefit from ICT. Verité Research is an interdisciplinary think tank in Colombo.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.